​​​

​​Biomedical Training

All-but-dissertation PhD Pharmacology, University of Pennsylvania School of Medicine, 1983

• Supported by a National Institutes of Health full tuition grant
  
• Completed all course requirements as a PhD candidate and voluntarily withdrew in good academic standing in my final year

MS Physiology, George Washington School of Medicine & Health Sciences, 1978

• Based on neuroscientific research at the National Institute of Mental Health in the laboratory of Nobel laureate Julius Axelrod
  

BS Zoology, George Washington University, 1975

Professional Experience: Strategic Marketing

​Consultant, Strategic Marketer, 8/09-present​

• Identify unique scientific or clinical features of new chemical entities that inform product development and commercialization
  
• Perform market analyses to characterize potential competitive environments at the time of product introduction or advanced life cycles
• Develop scientific platforms that support value propositions to differentiate and build brands
• Contribute to clinical protocol designs to generate outcomes that validate and support competitive marketing claims

Director, Clinical Strategy, S & R Communications Group, 3/05-8/09​

• Created communication plans (publications, presentations, digital media, relationship building) for full penetration of market targets with key messages
  
• Identified and developed relationships with thought leaders for advisory boards, publication faculty, convention presentations, and speaker’s bureaus
  
• Contributed to development and presentation of successful new business pitches
• Developed internal backgrounder presentations on diseases and products
• Developed REMS risk management programs
• Supervised internal and freelance medical writers
  

Professional Experience: Medical Writing, Educational

Consultant, Medical Writer, 9/94-1/04; 8/09-present

• Develop and execute communication plans (publications, presentations, digital media, relationship building) 
  
• Perform literature research 
  
• Ensure compliance with regulatory guidelines and requirements
• Write across multiple platforms and venues:
  • Journal articles (original research, reviews) and supplements
    
  • Slide presentations (podium presentations, advisory board meetings, speaker’s bureau presentations)
  • Meeting coverage and executive summaries
  • Exhibit abstracts and posters
  • CME needs assessments and program content
  • AMCP formulary dossiers or managed care kits, product monographs
  • Speeches, A/V scripts
  • Backgrounders, monographs, white papers
  • Sales training manuals

Onsite Contract Writer, Medical Affairs, G. D. Searle & Co., 6/98-12/98

• Assisted Research & Development staff in creation of journal articles in preparation for launch of Celebrex® (celecoxib)
  

Professional Experience: Medical Writing, Promotional

Creative Director, Sr VP, S & R Communications Group, 1/04-3/05

• Supervised creative staff of copywriters and art directors
• Led successful creative presentations for new business pitches

In the following positions, created promotional materials for direct and indirect marketing to physicians, pharmacists, nurses, managed care, sales representatives,and patient audiences:

• Assoc Creative Director, VP, Robert A Becker, 8/93-9/94
• Group Copy Supervisor, VP, KPR, 4/87-8/93
  
• Copy Supervisor, RW Rosenthal, 7/85-4/87
• Copywriter, WD McAdams, 1/84-7/85

Biomedical Research

• Eight years preclinical and clinical bench research and laboratory experience
  
  • Psychopharmacology Laboratory, VA Hospital of Philadelphia, 1982-1983
    
  • Clinical Pharmacology Laboratory, Children’s Hospital of Philadelphia, 1981-1982
  • Clinical Chemistry Laboratory, Children’s Hospital of Philadelphia, 1980-1983
  • Clinical Pharmacology Laboratory, NIAAA, 1977-1978
    
  • Preclinical Pharmacology Laboratory, NIMH, 1976-1977
    

Curriculum Vitae, Carol Gorman

​​​​​​​​PharmConsultant™

Building brands with targeted communications

​

Therapeutic Areas of Experience

Extensive experience, solid scientific background

Over 30 years creating medical communications

Two graduate degrees from highly respected medical schools (Univ Penn, Geo Wash Univ)

Eight years clinical research, pre-clinical bench research (NIH), and clinical laboratory experience (Children’s Hosp of Phila)

Extensive knowledge across a broad spectrum of therapeutic areas  

Targeted writing, multiple platforms for multiple audiences

• Journal articles, reviews, and supplements
  
• Meeting abstracts and posters
  
• Slide kits for podium presentations, advisory board meetings, and speaker’s bureau presentations
  
• Meeting coverage and executive summaries
  
• Continuing Medical Education needs assessments and program content
  
• Sales training manuals
  

Strategic market analyses, support across brand life cycles

• Identification of unique scientific or clinical features that establish a compelling marketing advantage
  
• Analyses of competitive market environment for drugs in all life cycles: at time of launch and beyond
  
• Scientific platforms that document support for value propositions
  
• Publication plans for full penetration of target audiences with key messages
  
• Identification and management of key thought leaders
  

RHEUMATOLOGY

Advisory Board Presentations
Metoject® for rheumatoid arthritis: scientific communication platform. National Advisory Board. Medac Pharma, Inc. 2012.

Metoject® for rheumatoid arthritis: regimen intensification for optimal control. National Advisory Board. Medac Pharma, Inc. 2013.

Continuing Medical Education
Highlights from the roundtable meeting of the council for the advancement of osteoarthritis management: Evolution and pharmacology of COX-1 and COX-2 inhibitors. Tim Warner, PhD. 2004.

Needs Assessment: Osteoarthritis management in the post-rofecoxib era: a closer look at pharmacologic options. 2010

Journal Article
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, Verburg KM, Isakson PC, Hubbard RC, Geis GS. Lancet. 1999;354(9196):2106-2111.

Monograph
IMPROVE: Clinical outcomes with meloxicam in office-based practices. Boehringer Ingelheim Pharmaceuticals, Inc. 2002.

Scientific Communication Platform
Metoject® Scientific Message Platform. Medac Pharma, Inc. 2012.

Speaker’s Bureau Presentation
Management of common arthritis disorders. David Yokum, MD, 2002.

VIROLOGY

CME Monographs
Combivir™ Tablets (lamivudine/zidovudine tablets). The clinical rationale. Glaxo Wellcome Inc. 1997.

Management of HIV with Kaletra. Abbott Laboratories. 2000.
Herpes virus management. Special considerations for the female patient. Harold A. Kessler, MD; David A. Baker, MD; Zane A. Brown, MD; Peter A. Leone, MD. Rush-Presbyterian-St. Luke’s Medical Center. 2002.

Strategies intended to make patient’s lives easier. A monograph based on a meeting to increase knowledge of simplification of HIV therapies. John A. Bartlett, MD; Tony Adinolfi, MSN, RN, ANP, ACRN; Steven Boswell, MD; Michael Norton, RPA-C, MPAS; Gary Reiter, MD, FACP; Pablo Tebas, MD. Duke School of Medicine. 2002.

Balancing trade-offs in HIV therapy. Renslow Sherer, MD, Harold A. Kessler, MD; Brian Boyle, MD; Eric Daar, MD; James I. Jones; MD, Kenneth A. Lichtenstein, MD;John D. Stansell, MD. Rush-Presbyterian-St. Luke’s Medical Center. 2003.

Preventing and managing HIV resistance in the clinical setting. Daniel R Kuritzkes, MD; Harold A Kessler, MD; Rafael E Campo, MD; Courtney Fletcher, PharmD; Joel E Gallant, MD, MPH; Michael Norton, PA; Peter Ruane, MD; Paul E. Sax, MD. Rush Presbyterian-St Luke’s Medical Center. 2003.

Optimizing care for African-American HIV patients. Kimberly Y. Smith MD, MPH; Michael L. Rapper, MD; Andre Brutus, MD; Ronald Cathcart, MD; Joseph Gathe, Jr, MD; William Johnson, MD; Wilbert Jordon, MD; Helena Kwakwa, MD, MPH; Joseph Nkwanou, MD; Carlos Page, MD; Robert Scott, MD; Anita C. Vaughn, MD; Luther A. Virgil, MD; Diana Williamson, MD, MSc. New York University Post-Graduate Medical School. 2003.

Needs Assessment: Clinical update on respiratory syncytial virus: what pharmacists need to know. 2009.

CME Needs Assessment
2011 Update: clinical management of influenza with antiviral agents. 20122.

CME Symposium
CONO 2012: Second annual combination and novel HCV therapies conference. 2012. Kadmon Corporation, LLC. 2012.

Journal Article
Antiretroviral activity of emtricitabine (FTC), a potent nucleoside reverse transcriptase inhibitor. Douglas D. Richman. Antiviral Therapy. 2001;6(2):83-88.

Poster Presentation
Prospective study of hyperlipidemia in ART-naïve subjects taking Trizivir (TZV), Combivir (COM)/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV. Kumar P, Rodriguez-French A, Thompson, M, Tashima, K, Wannamaker P, Williams V, Pappa K, McClernon D. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13-16, 2003. Poster #709.

Selected Bibliography​

ORIGINAL RESEARCH

Protein carboxymethylase and methyl-acceptor proteins in human platelets and erythrocytes. Robert F. O’Dea, O. Humberto Viveros, Ann Acheson, Carol Gorman, Julius Axelrod. Biochemical Pharmacology. 1978;27:679-684.

AUDIOLOGY

Advisory Board Presentation
Sonata cochlear implant for severely hearing impaired, presented to thought leader otology surgeons. MED-EL. 2008.

CARDIOLOGY

Advisory Board Presentation
Rosuvastatin HCP advisory board. AstraZeneca, 2012.

CME Needs Assessments
Management of diabetes following acute coronary syndrome: residual cardiovascular risk. 2011.
Uncontrolled hypertension or resistant hypertension? Strategies for improving management and control. 2011.

DERMATOLOGY

Audio/Video Scripts
Actinic keratoses. Interactive kiosk at American Academy of Dermatology annual meeting. 2011.
Combination therapy for acne: focus on efficacy. Stiefel Laboratories, Inc., 2012.
Combination therapy for acne: focus on safety and tolerability. Stiefel Laboratories, Inc., 2012.

CME Monographs
Management of dermatoses with Locoid® (hydrocortisone butyrate 0.1%). Ferndale Laboratories, Inc. 2003.
Innovations in facial aesthetic medicine: mastering the art and science of injectables. Merz Aesthetics, Inc. 2013.

Journal Article
Efficacy and safety of Tonel® topical oil improvement in toenail appearance and foot skin comfort correlated with consumer satisfaction. Richard H. Lowstuter, Jr, Charles J. Boegli. J Amer Pod Med Assoc. In press. 2013.

Journal Supplements
Combination therapy for the treatment of acne: Report of current concepts. Emil A. Tanghetti, MD; Guy F. Webster, MD, PhD; James Q. Del Russo, DO; Valerie D. Callender, MD. Cutis. 2005;76(2S).

Validated grading scales for aesthetic procedures. Alastair Carruthers, MD, Jean Carruthers, MD, Bhushan Hardas, MD, Mandeep Kaur, MD, MS, Roman Goertelmeyer, PhD, Derek Jones, MD, Berthold Rzany, MD, PhD, Joel Cohen, MD, Martina Kerscher, MD, PhD, Timothy Corcoran Flynn, MD, Corey Maas, MD, Gerhard Sattler, MD, Alexander Gebauer, MD, Rainer Pooth, MD, Kathleen McClure, RN, Ulli Simone-Korbel and Larry Buchner. Dermatologic Surgery. 2008;34(2).

MSL Slide Presentation
Actinic keratoses: disease overview and treatment options. LEO Pharma, Inc. 2011.

Scientific Communication Platform
Ingenol mebutate gel for actinic keratoses: scientific message platform. LEO Pharma, Inc., 2011.

Speaker’s Bureau Presentation
Treatment of actinic keratosis. LEO Pharma, Inc. 2011.

ENDOCRINOLOGY

Advisory Board Presentation
Expert panel on the evolving DPP4 landscape. Bristol-Myers Squibb and AstraZeneca, 2011.

KOL Development
KOL identification and development for PrandiMet for the treatment of type-2 diabetes. Sciele Pharma Inc. 2008.

Speaker’s Bureau Presentation
Getting to A1C goal. Presentation on PrandiMet for the treatment of type-2 diabetes to Advisory Board of KOL endocrinologists and diabetes treaters. Novo Nordisk and Sciele Pharma, Inc. 2008.

GASTROENTEROLOGY

Journal Articles
Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Douglas K Rex, MD FACP FACG. Annals of Pharmacotherapy. 2007;41(9):1466-1475.

Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Brian G Feagan MD, Geoffroy Coteur PhD, Seng Tan MSc, BPharm, Dorothy L Keininger MS, Pharm BS, Stefan Schreiber MD. American Journal of Gastroenterology.2009;104(8):1976-1983.

IMMUNOLOGY

CME Monograph
TOR inhibition. A new therapeutic pathway to immunosuppression. John F Neylan, MD; Conrad B Blum, MD; William E Harmon; Marc I Lorber, MD; Allan S MacDonald, MD; Randall E Morris, MD. American Society of Transplantation, 2000.

Monograph
Hereditary angioedema: the burden of illness, Shire Orphan Therapies, 2011.

Pharmacy and Therapeutics Dossier
Clinical summary: Firazyr® (icatibant injection) for hereditary angioedema. Shire Orphan Therapies, 2011.

Speaker’s Bureau Presentations
Firazyr: optimizing management of your patients with hereditary angioedema. Shire Orphan Therapies, 2013.

Gardasil vaccine: helping protect adolescents against certain HPV diseases. Merck & Co., Inc. 2011.

Menveo vaccine: Meningococcal disease: epidemiology, vaccines, and Menveo clinical data. Novartis Vaccines and Diagnostics, Inc., 2011.

Patient Education
Firazyr, your secret weapon in the fight against hereditary angioedema attacks. Shire Orphan Therapies, 2011.

METABOLIC DISORDERS

Journal Article
Hyponatremia in cirrhosis. Samuel H. Sigal. J Hosp Med. 2012;7(suppl 4):S14-S17.

Patient Education
How Type 1 Gaucher disease affects your bones. Shire, 2012.

Pharmacy and Therapeutics Dossier
Clinical Summary: Replagal (agalsidase alfa) for Fabry disease. Shire, 2012.

MICROBIOLOGY

CME Monographs
Gram-positive bacteria. Mechanisms of antibiotic action and bacterial resistance. Pharmacia and Upjohn, 2002.

Infections in the ICU; avoidable, not inevitable. Optimer Pharmaceuticals, Inc., 2012.

Community-acquired pneumonia: the emergency department as a pivotal point of care. Forest Laboratories, Inc., 2013.

CME Needs Assessments
Advances in science to improve care of acute bacterial skin and skin structure infections. Evidence-based strategies for managing ABSSSI in the hospital setting. 2012.

CME Symposium Presentation
ABSSSI and CABP: maximizing the anti-infective arsenal to optimize patient outcomes. IDWeek, October 2013.

Community-acquired bacterial pneumonia: the emergency department as a pivotal point of care. American College of Emergency Physicians. October, 2013.

Journal Article
Topical ofloxacin treatment of otorrhea in children with tympanostomy tubes. Joseph E. Dohar, MD; Eric T. Garner, MD; Richard W. Nielsen, MD; Merril A. Biel, MD, PhD; Mindell Seidlin, MD. Archives of Otolaryngology—Head & Neck Surgery. 1999;125(5):537-545.

NEUROLOGY

Advisory Board Presentation, International
Obtaining practice insights from key EU epileptologists to inform US marketing of Lundbeck anticonvulsant portfolio. Lundbeck, 2012.

CME Journal Reviews
Placebo-controlled trial of oral laquinimod for multiple sclerosis. 2012.

Subgroup analyses of placebo-controlled trial with an oral immunomodulator for the treatment of RRMS. 2012.

Placebo-controlled trial of vitamin D3 added to interferon beta for the treatment of RRMS. 2012.

CME Monographs
Management of depression complicated by treatment-emergent sexual dysfunction. Glaxo Wellcome. 1998.

Management of geriatric depression complicated by comorbid illness. Part 2. Clinical challenges in geriatric mental health. American Association for Geriatric Psychiatry. 2003.

CME Needs Assessment
Strategies for the management of multiple sclerosis: best practices for long-term control. 2012

Journal Articles
Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. Alberts MJ; Hademenos G; Latchaw RE; Jagoda A; Marler JR; Mayberg MR; Starke RD; Todd HW; Viste KM; Girgus M; Shephard T; Emr M; Shwayder P; Walker MD. JAMA. 2000;283(23):3102-3109. 

The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. Lisa H Lowe, Gregory L Kearns, James H Wible. Current Medical Research and Opinion. 2006;22(12):2515-2524.

Management of breakthrough seizures in the emergency department: continuity of patient care. Georgia D Montouris and Andy S Jagoda. Current Medical Research and Opinion. 2007;23(7):1583-1592.

Pharmacy and Therapeutics Dossier
Horizant® (gabapentin enacarbil) extended release tablets for restless legs syndrome. GSK and XenoPort, 2013.

Poster Presentations
EN3231, an NMDA-enhanced analgesic, provides effective analgesia, is opioid-sparing, and does not increase the incidence of adverse events in arthritis patients. Thomas G. Schlagheck, Bradley S. Galer, Arnold Gammaitoni, Barbara Nagle, Frank S. Caruso. American Society of Regional Anesthesia & Pain Medicine. Phoenix, Arizona; November 7-10, 2002. Poster #36.

The NMDA-enhanced analgesic EN3231 does not cause neurotoxicity in the posterior cingulate/retrosplenial region of the rat brain. Richard D Smith, Frank S Caruso. American Society of Regional Anesthesia & Pain Medicine. Phoenix, Arizona; November 7-10, 2002. Poster #19

Risk Evaluation and Mitigation Strategies Materials
Medication Guide, Healthcare Professional letters, Doctor and Patient brochures. Xenazine for the treatment of chorea associated with Huntington’s disease. Ovation. 2008.

Scientific Communication Platform
Suvorexant: first-in-class orexin receptor antagonist for the treatment for insomnia. Merck & Co., Inc. 2011.

Speaker’s Bureau Presentations
Bone mineral density and anticonvulsant therapy. Michael A. Levine, MD. 2003.

Migraine and comorbid conditions: Diagnosis and management. Richard B. Lipton, MD. GlaxoSmithKline. 2007.

Menstrual migraine: A clinician’s perspective. Lisa K. Mannix, MD. GlaxoSmithKline. 2007.

Multiple mechanisms of migraine: the evolving picture of migraine pathophysiology. K.M.A. Welch, MB, ChB, FRCP. GlaxoSmithKline. 2007.

Qutenza® (capsaicin) 8% patch for postherpetic neuralgia. Allergan, Inc. 2011.

Training Materials
MSL training slide deck on the treatment of chronic inflammatory demyelinating polyneuropathies with Gamunex. 2007

Sales training manual on the treatment of chorea associated with Huntington’s disease with Xenazine. 2008

Vivitrol® (naltrexone): managing opioid dependence. Alkermes, Inc., 2011.

ONCOLOGY

Audio/Video Script
Adherex Technologies. The leader in bringing cadherin antagonists to oncotherapy. 2004.

CME Needs Assessment
Pharmaceutical management of chronic myeloid leukemia: finding the optimal strategy. 2009.

KOL Development
KOL identification and development for TheraSphere for the treatment of advanced hepatocellular carcinoma. MDS Nordion. 2009.

Monographs
Xeloda® (capecitabine) in the treatment of metastatic breast cancer. Roche Laboratories Inc. 2003.

Xeloda® (capecitabine) in the treatment of metastatic colorectal cancer. Roche Laboratories Inc. 2003.

Scientific Communication Plan
Scientific communication plan for TheraSphere for the treatment of advanced hepatocellular carcinoma. MDS Nordion. 2009.

Training Materials
Modular Home Study Learning System for sales representatives; Pixantrone for the treatment of non-Hodgkin lymphoma. 2009.

OPHTHALMOLOGY

CME Monographs
Diagnosis and management of comorbid allergic conjunctivitis and dry eye disease. 2012.

Diagnosis and management of rheumatoid arthritis-related dry eye disease. 2012.

Diagnosis and management of dry eye disease secondary to ocular rosacea and atopic keratoconjunctivitis. 2012.

CME Needs Assessment
Eye openers: patient considerations in the treatment of dry eye disease. 2013.